Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial
Clinical Infectious Diseases · 08.02.2023 · 76 (3) · e1177-e1185
DOI: 10.1093/cid/ciac643 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 27.09.2022. Verfasst von Ahmed M Musa und 26 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan. Hauptthemen laut MEDLINE: Antiprotozoal Agents, Leishmaniasis, Visceral. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European and Developing Countries Clinical Trials Partnership, Dutch Ministry of Foreign Affairs, Federal Ministry of Education and Research.
Abstract (Originalsprache)
Background
This study aimed to determine whether paromomycin plus miltefosine (PM/MF) is noninferior to sodium stibogluconate plus paromomycin (SSG/PM) for treatment of primary visceral leishmaniasis in eastern Africa.
Methods
An open-label, phase 3, randomized, controlled trial was conducted in adult and pediatric patients at 7 sites in eastern Africa. Patients were randomly assigned to either 20 mg/kg paromomycin plus allometric dose of miltefosine (14 days), or 20 mg/kg sodium stibogluconate plus 15 mg/kg paromomycin (17 days). The primary endpoint was definitive cure after 6 months.
Results
Of 439 randomized patients, 424 completed the trial. Definitive cure at 6 months was 91.2% (155 of 170) and 91.8% (156 of 170) in the PM/MF and SSG/PM arms in primary efficacy modified intention-to-treat analysis (difference, 0.6%; 97.5% confidence interval [CI], −6.2 to 7.4), narrowly missing the noninferiority margin of 7%. In the per-protocol analysis, efficacy was 92% (149 of 162) and 91.7% (155 of 169) in the PM/MF and SSG/PM arms (difference, −0.3%; 97.5% CI, –7.0 to 6.5), demonstrating noninferiority. Treatments were well tolerated. Four of 18 serious adverse events were study drug–related, and 1 death was SSG-related. Allometric dosing ensured similar MF exposure in children (<12 years) and adults.
Conclusions
PM/MF and SSG/PM efficacies were similar, and adverse drug reactions were as expected given the drugs safety profiles. With 1 less injection each day, reduced treatment duration, and no risk of SSG-associated life-threatening cardiotoxicity, PM/MF is a more patient-friendly alternative for children and adults with primary visceral leishmaniasis in eastern Africa. Clinical Trials Registration NCT03129646.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.
- Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya.
- Leishmaniasis Research and Treatment Center, University of Gondar, Gondar, Ethiopia.
- Department of Immunology and Molecular Biology, Leishmaniasis Unit, College of Health Sciences, Makerere University, Kampala, Uganda.
- Médecins sans Frontières, OCA, Amsterdam, The Netherlands.
- Médecins sans Frontières, OCG, Geneva, Switzerland.
Förderung
- European and Developing Countries Clinical Trials Partnership
- Dutch Ministry of Foreign Affairs
- Federal Ministry of Education and Research
- Medicor Foundation
- Médecins sans Frontières International,
- Swiss Agency for Development and Cooperation
- Dutch Research Council
Zitieren
APA
Musa, A. M., Mbui, J., Mohammed, R., Olobo, J., Ritmeijer, K., Alcoba, G., Muthoni Ouattara, G., Egondi, T., Nakanwagi, P., Omollo, T., Wasunna, M., Verrest, L., Dorlo, T. P. C., Musa Younis, B., Nour, A., Taha Ahmed Elmukashfi, E., Ismail Omer Haroun, A., Khalil, E. A. G., Njenga, S., …, & Alves, F. (2023). Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial. Clinical Infectious Diseases, 76(3), e1177-e1185. https://doi.org/10.1093/cid/ciac643
Vancouver
Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer K, Alcoba G, et al. Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial. Clinical Infectious Diseases. 2023;76(3):e1177-e1185. doi:10.1093/cid/ciac643
BibTeX
@article{Musa2023,
author = {Musa, Ahmed M and Mbui, Jane and Mohammed, Rezika and Olobo, Joseph and Ritmeijer, Koert and Alcoba, Gabriel and Muthoni Ouattara, Gina and Egondi, Thaddaeus and Nakanwagi, Prossy and Omollo, Truphosa and Wasunna, Monique and Verrest, Luka and Dorlo, Thomas P C and Musa Younis, Brima and Nour, Ali and Taha Ahmed Elmukashfi, Elmukashfi and Ismail Omer Haroun, Ahmed and Khalil, Eltahir A G and Njenga, Simon and Fikre, Helina and Mekonnen, Tigist and Mersha, Dagnew and Sisay, Kasaye and Sagaki, Patrick and Alvar, Jorge and Solomos, Alexandra and Alves, Fabiana},
title = {Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial},
journal = {Clinical Infectious Diseases},
year = {2023},
volume = {76},
number = {3},
pages = {e1177--e1185},
doi = {10.1093/cid/ciac643}
}
EUVIMED